# GLP Life Sciences > GLP-1 Research Compounds · Documented to the Batch ## Posts - [Peptide Purity vs Net Peptide Content: How to Read a COA](https://glp-life.com/peptide-purity-vs-net-peptide-content/): Learn why HPLC purity and net peptide content are different measurements and how to verify what a peptide certificate actually reports. - [HPLC vs LC-MS for Peptide Testing: What Each Can Show](https://glp-life.com/hplc-vs-lc-ms-peptide-testing/): Compare HPLC and LC-MS for peptide testing and learn what chromatographic purity, mass data and identity checks can show on a COA. - [Tirzepatide SURMOUNT-OSA and the 52-Week AHI Results](https://glp-life.com/tirzepatide-surmount-osa-ahi-results/): Read the 52-week tirzepatide SURMOUNT-OSA results, including the AHI endpoint and why the trials enrolled different PAP groups. - [What Retatrutide TRIUMPH-Outcomes Measures for Heart and Kidney Health](https://glp-life.com/retatrutide-triumph-outcomes-heart-kidney/): Learn how the retatrutide TRIUMPH-Outcomes trial differs from weight-loss trials and what its cardiovascular and kidney outcomes can show. - [Retatrutide TRANSCEND-T2D-1 and the 40-Week A1C Results](https://glp-life.com/retatrutide-transcend-t2d-1-a1c/): Find out what the 40-week retatrutide TRANSCEND-T2D-1 trial measured and how it differs from the TRIUMPH-2 obesity study. - [Tirzepatide SURMOUNT-1: Reading the 72-Week Results](https://glp-life.com/tirzepatide-surmount-1-trial-results/): Understand the tirzepatide SURMOUNT-1 study at 72 weeks, including its population, placebo comparison, outcomes and limitations. - [Tirzepatide Mechanism of Action at GIP and GLP-1 Receptors](https://glp-life.com/tirzepatide-mechanism-gip-glp-1/): Learn how tirzepatide activates GIP and GLP-1 receptors and what cell-based studies mean by imbalanced or biased agonism. - [Tirzepatide SURMOUNT-4 and the Weight Maintenance Question](https://glp-life.com/tirzepatide-surmount-4-withdrawal-trial/): Understand the tirzepatide SURMOUNT-4 withdrawal design and why its week-88 results use week 36 as the comparison point. - [Retatrutide TRIUMPH-3 and Established Cardiovascular Disease](https://glp-life.com/retatrutide-triumph-3-cardiovascular-disease/): Review what Lilly reported from TRIUMPH-3 in adults with severe obesity and cardiovascular disease, and what the trial measured. - [Retatrutide TRIUMPH-2 Results in Obesity and Type 2 Diabetes](https://glp-life.com/retatrutide-triumph-2-type-2-diabetes/): Read the 80-week retatrutide TRIUMPH-2 results in adults with obesity or overweight and type 2 diabetes, with the placebo comparison. - [Retatrutide and Liver Fat: What the MASLD Substudy Measured](https://glp-life.com/retatrutide-masld-liver-fat-study/): A randomized Phase 2a substudy evaluated participants with elevated liver fat. Its main measure was relative change in liver fat at 24 weeks, assessed within a selected group from the obesity study. - [Primary vs Secondary Endpoints in Retatrutide Trials](https://glp-life.com/retatrutide-primary-secondary-endpoints/): The retatrutide Phase 2 obesity study designated percentage change in body weight at 24 weeks as its primary endpoint. The frequently cited 48-week weight changes came from later follow-up. - [Retatrutide Trial Estimands Explained in Plain English](https://glp-life.com/retatrutide-trial-estimand/): An estimand specifies the effect a study is trying to estimate. It describes the population, endpoint and handling of events such as discontinuing the assigned treatment. - [Retatrutide Discontinuation Rates: What to Check](https://glp-life.com/retatrutide-discontinuation-rates/): Trial reports can distinguish stopping because of an adverse event, withdrawing from the study and stopping assigned treatment while continuing follow-up. These categories affect the evidence differently. - [Heart Rate in the Retatrutide Phase 2 Obesity Trial](https://glp-life.com/retatrutide-heart-rate-study/): The Phase 2 obesity publication described dose-dependent increases in heart rate that peaked at 24 weeks and declined later. The result is one of several safety observations reported by investigators. - [Retatrutide and Gastrointestinal Adverse Events](https://glp-life.com/retatrutide-gastrointestinal-adverse-events/): Gastrointestinal adverse events were prominent in the retatrutide obesity program. Studies generally report the type of event and how frequently it was observed in each group. - [Retatrutide Side Effects Reported in Obesity Trials](https://glp-life.com/retatrutide-trial-side-effects/): Gastrointestinal events were the most common adverse events in the retatrutide Phase 2 obesity trial. The study also reported a dose-related increase in heart rate that peaked during follow-up and then declined. - [Retatrutide Evidence: When Can a Study Establish a Winner?](https://glp-life.com/which-weight-loss-trial-shows-superiority/): A superiority result applies to a defined outcome, comparison, population and time point. SURMOUNT-5 found greater mean weight reduction with tirzepatide than semaglutide over 72 weeks in its tested population. - [Obesity With and Without Type 2 Diabetes: Reading Trial Comparisons](https://glp-life.com/retatrutide-obesity-with-vs-without-diabetes/): TRIUMPH-1 studied adults with obesity without diabetes. Other parts of the retatrutide program include adults with type 2 diabetes, often under separate trial protocols. - [Treatment Effects vs Headlines in Retatrutide Comparisons](https://glp-life.com/retatrutide-comparative-treatment-effect/): A headline commonly highlights one arm and one analysis. The study may also include other target amounts, alternate estimands, adverse events and outcomes with different levels of certainty. - [How to Compare Placebo-Adjusted Weight Loss in Obesity Trials](https://glp-life.com/placebo-adjusted-weight-loss-trials/): A placebo-adjusted comparison subtracts the estimated placebo change from the estimated intervention change within a trial. The result is expressed in percentage points when the original outcome is percent change. - [Retatrutide vs Tirzepatide: Which Has the Stronger Weight-Loss Evidence?](https://glp-life.com/retatrutide-vs-tirzepatide/): Retatrutide showed substantial weight reductions in placebo-controlled obesity trials. Tirzepatide has its own randomized obesity studies, including SURMOUNT-1, with different populations and time points. - [Retatrutide Dosage and Tolerability in the Phase 2 Study](https://glp-life.com/retatrutide-dose-tolerability/): In the Phase 2 obesity trial, gastrointestinal adverse events were the most common and were dose related. The paper also described changes in heart rate during follow-up. - [Retatrutide Trial Frequency and Study Duration Explained](https://glp-life.com/retatrutide-weekly-clinical-trial-design/): Retatrutide obesity studies evaluated a once-weekly investigational intervention. Measurements used for the primary outcome were collected at prespecified follow-up points. - [Target Amount vs Assigned Regimen in Retatrutide Trials](https://glp-life.com/retatrutide-target-dose-trial-design/): A trial’s target amount is the label used for an assigned group. The study protocol specifies how participants were monitored and how the assigned intervention was managed over time. - [How Researchers Interpret Retatrutide Dose Response](https://glp-life.com/retatrutide-dose-response-study/): Dose-ranging trials measure whether group-level outcomes change across assigned amounts. Retatrutide Phase 2 results showed a pattern of greater mean weight reduction in higher target groups. - [Retatrutide 12 mg: Phase 2 and TRIUMPH-1 Results](https://glp-life.com/retatrutide-12-mg-trial-results/): The 12 mg Phase 2 arm had an estimated mean weight reduction of 24.2% at 48 weeks. The sponsor’s TRIUMPH-1 efficacy analysis reported a 28.3% mean reduction at 80 weeks in its 12 mg arm. - [Retatrutide 9 mg: The TRIUMPH-1 Research Arm](https://glp-life.com/retatrutide-9-mg-triumph-1/): The sponsor reported 25.9% average weight reduction at 80 weeks in the TRIUMPH-1 9 mg arm under its efficacy analysis, versus 2.2% with placebo. - [Retatrutide 8 mg: Reading the Phase 2 Results](https://glp-life.com/retatrutide-8-mg-phase-2/): At 48 weeks, the combined 8 mg Phase 2 groups had an estimated mean weight change of −22.8%. The paper also reports results for the placebo group and the other assigned amounts. - [Retatrutide 4 mg: Phase 2 and Phase 3 Research Arms](https://glp-life.com/retatrutide-4-mg-trial-results/): The Phase 2 obesity trial reported −17.1% mean weight change at 48 weeks in the combined 4 mg groups. The sponsor’s TRIUMPH-1 efficacy analysis reported −19.0% at 80 weeks in the 4 mg arm. - [Retatrutide 1 mg: What the Phase 2 Arm Found](https://glp-life.com/retatrutide-1-mg-study-arm/): The Phase 2 paper reported an estimated mean weight change of −8.7% at 48 weeks in the 1 mg retatrutide group, compared with −2.1% in the shared placebo group. - [Retatrutide Dosage in Clinical Trials: What Was Studied?](https://glp-life.com/retatrutide-clinical-trial-dosage/): The Phase 2 obesity study reported outcomes across 1 mg, 4 mg, 8 mg and 12 mg assigned groups. The Phase 3 TRIUMPH-1 paper describes 4 mg, 9 mg and 12 mg research arms. - [Retatrutide at 104 Weeks: Reading the Extension Data](https://glp-life.com/retatrutide-104-week-extension/): Lilly reported an extension of TRIUMPH-1 for 532 participants who had a baseline BMI of at least 35 and completed and tolerated treatment in the main study. Follow-up extended to 104 weeks. - [TRIUMPH-1: What the 28.3% Figure Measures](https://glp-life.com/retatrutide-28-3-percent-weight-loss/): The 28.3% figure is an average reduction for the 12 mg trial arm at 80 weeks under the sponsor-reported efficacy analysis. The corresponding placebo estimate was 2.2%. - [TRIUMPH-1 Retatrutide Phase 3 Weight-Loss Results](https://glp-life.com/triumph-1-retatrutide-weight-loss/): TRIUMPH-1 compared retatrutide with placebo over 80 weeks. In the sponsor’s efficacy analysis, the 12 mg arm showed a 28.3% average reduction in body weight, compared with 2.2% with placebo. - [Retatrutide Phase 2 Results at 24 Weeks](https://glp-life.com/retatrutide-24-week-results/): At 24 weeks, the Phase 2 paper reported an estimated mean change of −17.5% in the 12 mg group and −1.6% in the placebo group. This time point was specified for the primary weight endpoint. - [Retatrutide Phase 2 Weight-Loss Results at 48 Weeks](https://glp-life.com/retatrutide-phase-2-weight-loss/): The randomized Phase 2 trial enrolled 338 adults and compared several retatrutide groups with placebo. At week 48 the 12 mg group had an estimated mean weight change of −24.2%, compared with −2.1% with placebo. - [Retatrutide Evidence by Phase: Phase 2 and Phase 3](https://glp-life.com/retatrutide-phase-2-vs-phase-3/): Phase 2 obesity research tested multiple retatrutide groups against placebo and characterized weight change and adverse events. Phase 3 studied larger populations under new protocols. - [How to Read a Retatrutide Trial Registry Entry](https://glp-life.com/retatrutide-trial-registry/): ClinicalTrials.gov records contain a study identifier, planned outcomes, eligibility rules and sponsor-provided status information. The registration lets readers trace a protocol across news reports and papers. - [Retatrutide, GLP-3 and Search Terminology](https://glp-life.com/retatrutide-glp-3-terminology/): Readers may encounter GLP-3 as a catalog or search term. The clinical literature names the investigational molecule retatrutide or LY3437943 and identifies its targets as GLP-1, GIP and glucagon receptors. - [Retatrutide and the Meaning of an Investigational Medicine](https://glp-life.com/retatrutide-investigational-medicine/): As of November 6, 2026, retatrutide remains investigational in the United States. Published trial findings and regulatory approval are different milestones. - [Triple Agonist vs Dual Agonist vs Single Agonist](https://glp-life.com/triple-agonist-vs-dual-agonist/): The terms single, dual and triple refer to the number of receptor targets. Semaglutide targets GLP-1, tirzepatide targets GLP-1 and GIP, and retatrutide targets GLP-1, GIP and glucagon. - [What the Glucagon Receptor Adds to Retatrutide’s Design](https://glp-life.com/retatrutide-glucagon-receptor/): Glucagon receptor activity distinguishes retatrutide’s target profile from that of tirzepatide and semaglutide. Research on the combined profile includes effects on body weight and metabolic measures. - [How to Verify Retatrutide Claims Before Sharing Them](https://glp-life.com/verify-retatrutide-weight-loss-claims/): Start with the original trial paper or registered study record. Identify the intervention, comparator, population, follow-up and statistical analysis before quoting an outcome. - [Retatrutide and Obstructive Sleep Apnea: Reading the Trial Endpoint](https://glp-life.com/retatrutide-obstructive-sleep-apnea-trial/): Nested Phase 3 sleep-apnea trials assessed change in the apnea–hypopnea index. This index counts breathing interruptions or reductions per hour of sleep. - [Retatrutide and Knee Osteoarthritis: How TRIUMPH-4 Was Designed](https://glp-life.com/retatrutide-triumph-4-knee-osteoarthritis/): TRIUMPH-4 enrolled participants with obesity or overweight and knee osteoarthritis. The design assessed body weight and knee symptoms within the same research program. - [Why Cross-Trial Weight-Loss Rankings Can Mislead](https://glp-life.com/cross-trial-weight-loss-comparison/): A 48-week study and an 80-week study measure outcomes over different periods. Enrollment, baseline characteristics, comparator conditions and analytical methods can also differ. - [TRIUMPH-5: The Retatrutide and Tirzepatide Head-to-Head Trial](https://glp-life.com/triumph-5-retatrutide-tirzepatide-trial/): TRIUMPH-5 is registered as NCT06662383. Its direct comparison tests both treatments in adults with obesity using a shared trial protocol. - [Retatrutide vs Tirzepatide vs Semaglutide: A Study-by-Study Guide](https://glp-life.com/retatrutide-tirzepatide-semaglutide-comparison/): TRIUMPH-1, SURMOUNT-1 and STEP 1 are placebo-controlled studies of different interventions. Their published figures belong to their own populations, regimens, follow-up and analyses. - [Tirzepatide vs Semaglutide: What SURMOUNT-5 Found](https://glp-life.com/tirzepatide-vs-semaglutide-surmount-5/): In SURMOUNT-5, adults with obesity without diabetes were randomized to tirzepatide or semaglutide. At 72 weeks the estimated mean weight reduction was 20.2% with tirzepatide and 13.7% with semaglutide. - [Retatrutide vs Semaglutide: Obesity Trial Evidence Compared](https://glp-life.com/retatrutide-vs-semaglutide/): Retatrutide’s TRIUMPH-1 and semaglutide’s STEP 1 both used placebo comparators. They enrolled different study populations and assessed weight change at different times. - [Retatrutide Trial Results and Individual Variation](https://glp-life.com/retatrutide-individual-weight-loss-variation/): A study average combines a range of outcomes. Participants can reach different weight-loss thresholds, experience different adverse events, or discontinue assigned treatment. - [Reading Retatrutide Trial Graphs and Weight Curves](https://glp-life.com/retatrutide-weight-loss-curve/): A weight-change curve shows estimated group outcomes across scheduled visits. The horizontal axis usually shows time, and the vertical axis shows mean change from baseline. - [What Placebo Groups Tell Us in Retatrutide Trials](https://glp-life.com/retatrutide-placebo-group-results/): A placebo group helps researchers estimate how an intervention performed relative to the conditions of that trial. Changes can occur in both arms during follow-up. - [Retatrutide Trial Results: Percent Weight Loss vs Pounds](https://glp-life.com/retatrutide-weight-loss-percent-vs-pounds/): Percentage weight change relates the change to baseline weight. Pounds and kilograms describe absolute change. A given percentage represents different amounts at different starting weights. - [What Retatrutide Trials Mean by 20%, 25% and 30% Weight Loss](https://glp-life.com/retatrutide-weight-loss-thresholds/): A responder analysis counts the share of participants who reached a defined reduction from baseline weight. A mean change averages the estimated weight change for a group. - [GIP Receptor Activity in Retatrutide Research](https://glp-life.com/retatrutide-gip-receptor/): GIP stands for glucose-dependent insulinotropic polypeptide. Retatrutide and tirzepatide both engage the GIP receptor as part of a multi-receptor design. - [GLP-1 Receptor Activity in Retatrutide Research](https://glp-life.com/retatrutide-glp-1-receptor/): GLP-1 is one of the three receptors activated by retatrutide. It is also the target of semaglutide, which makes shared receptor activity an easy point of comparison at the molecular level. - [What Does LY3437943 Mean in Retatrutide Research?](https://glp-life.com/ly3437943-retatrutide/): LY3437943 is the development code for retatrutide. Registry titles often put the code in parentheses because development programs may use both the code and the generic name. - [What Is Retatrutide? The Triple Agonist Explained](https://glp-life.com/retatrutide-triple-agonist/): Retatrutide, also known as LY3437943, is an investigational peptide designed to activate the GLP-1, GIP and glucagon receptors. The three receptor targets are features of the molecule’s design. - [How to read a Certificate of Analysis, and what it cannot tell you](https://glp-life.com/how-to-read-a-certificate-of-analysis/): What a Certificate of Analysis records, which four fields matter, why the lot number is the load-bearing one, and what a COA cannot tell you. - [What retatrutide costs, and what the price is actually paying for](https://glp-life.com/what-retatrutide-costs/): Retatrutide 10 mg from $84, 20 mg from $120, 30 mg from $185. What drives price differences between suppliers, and why per-lot testing is part of the cost. - [Is retatrutide FDA approved? The regulatory status, stated plainly](https://glp-life.com/is-retatrutide-fda-approved/): Retatrutide is an investigational compound and is not FDA approved for any use. What investigational status means, and what research use only means. - [Does retatrutide need to be refrigerated? Storage and handling of lyophilised material](https://glp-life.com/does-retatrutide-need-to-be-refrigerated/): Sealed lyophilised retatrutide is stored at −20 °C or below, not in a refrigerator. Why the dry sealed state matters, why vials are equilibrated before opening, and why ambient shipping is normal. ## Pages - [Terms](https://glp-life.com/terms/): Effective November 7, 2026 1. About this site GLP Life Sciences operates this storefront at glp-life.com. These terms cover use of the website and requests or orders placed through it. 2. Research use only Products are offered for laboratory research. You must be at least 21 and be a qualified researcher or act on behalf of a qualified laboratory or institution. Products are not for human or veterinary use, consumption, diagnosis, or treatment. See the research use notice. 3. Product listings and orders Amounts shown in milligrams describe the nominal contents of a vial. Review the product details and your order ... Read more - [Refund and Returns Policy](https://glp-life.com/refunds/): Effective November 7, 2026 1. If there’s a problem with your order If your shipment arrives damaged, contains an incorrect item, or is missing an item, email contact@glp-life.com promptly. Include your order number and a description of the problem. Photos of the package or item can help us review damage or a mix-up. 2. Requesting a return Email us with your order number and tell us which unopened item you want to return and why. We review requests individually and will confirm the options and any return instructions. Wait for those instructions before sending anything back. 3. Cancellations and shipping delays ... Read more - [Shipping](https://glp-life.com/shipping/): Shipping inquiries For current shipping availability, charges and estimated delivery, contact GLP Life Sciences before placing an order. If you are asking about an existing order, include the order number and destination postal code. Email GLP Life Sciences - [Contact](https://glp-life.com/contact/): Contact GLP Life Sciences For product, order, shipping or lot-documentation questions, email our team. Include the order number or lot number if it relates to your question. contact@glp-life.com - [Research use](https://glp-life.com/research-use/): Laboratory research use notice GLP Life Sciences reference compounds are supplied for laboratory research use only. They are not for human or veterinary use or consumption, and are not for diagnostic, therapeutic or clinical application. The site asks visitors to confirm their age and research eligibility before viewing products. Browse research articles - [Quality](https://glp-life.com/quality/): Quality and testing information To check documentation for a vial, locate its lot number on the label and search for that number in the COA library. When a report is available, review the lot identifier, analytical method and reported results before relying on it. For help locating a report, email GLP Life Sciences with the product name and lot number. Open the COA library · Email GLP Life Sciences - [About](https://glp-life.com/about/): About GLP Life Sciences GLP Life Sciences lists reference compounds for laboratory research. The catalog identifies each compound and nominal vial content. Use the COA library to look up available documentation for a specific lot. Browse compounds · Open the COA library - [Retatrutide Research Guide: Weight Loss, Dosage Studies and Comparisons](https://glp-life.com/retatrutide-research-guide/): An evidence guide to retatrutide weight-loss trials, assigned research arms, adverse events and comparative studies. - [Research](https://glp-life.com/research/) - [COA library](https://glp-life.com/coa/): Certificates of Analysis COA library Every released lot has its own Certificate of Analysis, stating the analytical method, the purity result and the date of analysis for that lot — not a catalogue-wide figure. Enter the lot number printed on your vial label or carton. Released lots - [Home](https://glp-life.com/): Retatrutide and tirzepatide peptide for laboratory research use only. Retatrutide 10/20/30 mg from $84, with a COA for every lot. - [Waitlist](https://glp-life.com/waitlist/): Join the waitlist for a GLP Life Sciences lot. - [My account](https://glp-life.com/my-account/) - [Checkout](https://glp-life.com/checkout/) - [Cart](https://glp-life.com/cart/) - [Shop](https://glp-life.com/shop/) - [Privacy Policy](https://glp-life.com/privacy/): Effective November 7, 2026 1. Information we collect When you place an order, we collect contact, billing and order information, and shipping details when applicable. The waitlist collects your email address. If you contact us, we receive your message and any information you include. 2. How we use it We use this information to process orders, send order and waitlist updates, answer questions, and operate and protect the site. Site analytics help us understand which pages people visit. 3. Cookies and browser storage The research-use notice uses browser storage to remember your acknowledgment. Essential cookies may support cart, checkout or account ... Read more ## Products - [Tirzepatide 20 mg](https://glp-life.com/product/tirzepatide-20-mg/): Tirzepatide 20 mg (LY3298176), SKU TZ20. One sealed glass vial of lyophilized powder for laboratory research use only. - [Tirzepatide 10 mg](https://glp-life.com/product/tirzepatide-10-mg/): Tirzepatide 10 mg (LY3298176), SKU TZ10. One sealed vial of lyophilized powder for laboratory research use only. See product specifications. - [Retatrutide 30 mg](https://glp-life.com/product/retatrutide-30-mg/): Retatrutide 30 mg per vial (RT30), the largest Retatrutide vial size in our catalog. Choose a one-, two-, or three-vial laboratory research pack. - [Retatrutide 20 mg](https://glp-life.com/product/retatrutide-20-mg/): Retatrutide 20 mg (LY3437943), SKU RT20. Lyophilized powder for laboratory research, with 20 mg in each vial and three pack sizes. - [Retatrutide 10 mg](https://glp-life.com/product/retatrutide-10-mg/): Retatrutide 10 mg per vial, SKU RT10. Compare one-, two-, and three-vial packs of lyophilized LY3437943 for laboratory research use only. ## Optional - [Agent (MCP protocol)](websites-agents.hostinger.com/glp-life.com/mcp) [comment]: # (Generated by Hostinger Tools Plugin)